Novavax (NVAX) Current Leases (2012 - 2026)

Novavax's Current Leases history runs 10 years deep, the most recent figure standing at $2.1 million for Q1 2026.

• In Q1 2026, Current Leases fell 61.45% year-over-year to $2.1 million; the TTM figure through Mar 2026 stood at $2.1 million (down 61.45% YoY), while the FY2025 annual figure was $2.5 million, down 85.34% from the prior year.
• Current Leases was $2.1 million for Q1 2026 at Novavax, down from $2.5 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $124.3 million in Q2 2022 to a low of $953000.0 in Q2 2023.
• Historically, Current Leases has averaged $25.8 million across 5 years, with a median of $5.6 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Current Leases plunged 99.23% in 2023, then soared 889.19% in 2024.
• A 5-year view of Current Leases shows it stood at $44.1 million in 2022, then slumped by 88.33% to $5.1 million in 2023, then jumped by 232.61% to $17.1 million in 2024, then sank by 85.34% to $2.5 million in 2025, then dropped by 15.76% to $2.1 million in 2026.
• The last three Current Leases figures came in at $2.1 million (Q1 2026), $2.5 million (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.